Estrella Immunopharma (ESLA)
NASDAQ:ESLA
Total Valuation
Estrella Immunopharma has a market cap or net worth of $81.92M. The enterprise value is $80.53M.
Market Cap$81.92M
Enterprise Value$80.53M
Share Statistics
Estrella Immunopharma has 42,665,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,665,230
Owned by Insiders―
Owned by Institutions0.07%
Financial Efficiency
Estrella Immunopharma’s return on equity (ROE) is 1.26 and return on invested capital (ROIC) is 126.01%.
Return on Equity (ROE)1.26
Return on Assets (ROA)-4.11
Return on Invested Capital (ROIC)126.01%
Return on Capital Employed (ROCE)1.26
Revenue Per Employee0.00
Profits Per Employee-4.35M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Estrella Immunopharma is ―. Estrella Immunopharma’s PEG ratio is -0.11.
PE Ratio―
PS Ratio0.00
PB Ratio-5.54
Price to Fair Value-5.54
Price to FCF-32.17
Price to Operating Cash Flow-36.57
PEG Ratio-0.11
Income Statement
In the last 12 months, Estrella Immunopharma had revenue of 0.00 and earned -13.06M in profits. Earnings per share was -0.35.
Revenue0.00
Gross Profit0.00
Operating Income-13.06M
Pretax Income-13.06M
Net Income-13.06M
EBITDA-13.06M
Earnings Per Share (EPS)-0.35
Cash Flow
In the last 12 months, operating cash flow was -1.79M and capital expenditures 0.00, giving a free cash flow of -1.79M billion.
Operating Cash Flow-1.79M
Free Cash Flow-1.79M
Free Cash Flow per Share-0.04
Dividends & Yields
Estrella Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.47
52-Week Price Change110.99%
50-Day Moving Average1.18
200-Day Moving Average1.33
Relative Strength Index (RSI)82.26
Average Volume (3m)165.74K
Important Dates
Estrella Immunopharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Estrella Immunopharma as a current ratio of 0.12, with Debt / Equity ratio of 0.00%
Current Ratio0.12
Quick Ratio0.12
Debt to Market Cap0.00
Net Debt to EBITDA0.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Estrella Immunopharma has paid 838.00 in taxes.
Income Tax838.00
Effective Tax Rate>-0.01
Enterprise Valuation
Estrella Immunopharma EV to EBITDA ratio is -4.29, with an EV/FCF ratio of -31.39.
EV to Sales0.00
EV to EBITDA-4.29
EV to Free Cash Flow-31.39
EV to Operating Cash Flow-31.39
Balance Sheet
Estrella Immunopharma has $1.38M in cash and marketable securities with $0.00 in debt, giving a net cash position of $1.38M billion.
Cash & Marketable Securities$1.38M
Total Debt$0.00
Net Cash$1.38M
Net Cash Per Share$0.03
Tangible Book Value Per Share-$0.28
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Estrella Immunopharma is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―